Hopp til innhold

Get alerts of updates about «Plasma concentration of perfluoroalkyl substances (PFAS) in relation to menstrual characteristics»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Plasma concentration of perfluoroalkyl substances (PFAS) in relation to menstrual characteristics

Project

Plasma concentration of perfluoroalkyl substances (PFAS) in relation to menstrual characteristics - project description

Published Updated

Our project will allow an enhanced assessment of why menses-related outcomes are related to PFAS concentrations.


Summary

In addition to exposure, elimination from the human body is an important determinant of PFAS concentrations in plasma. Given that PFASs are stored in plasma, with 95% of the chemical being bound to albumin, one important pathway of elimination may be menstruation. Menstrual fluid has a high concentration of albumin which is lost with each menses. Partly because of this loss through menstruation, lower plasma levels of PFOS and PFOA and shorter elimination half-life have been observed in women compared to men. Understanding PFAS loss through menstruation is critical in the study of the effects of these chemicals on women’s health. The concentration of PFAS in plasma has been associated with earlier age at menopause, endometriosis, and alterations of the menstrual cycle. However, the associations observed in these studies may be due to physiological and pharmacokinetic phenomena related to PFAS loss through menstruation rather than an adverse effect of PFAS. Our project will allow an enhanced assessment of why menses-related outcomes are related to PFAS concentrations.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Line Småstuen Haug, Avdeling for miljøeksponering og -epidemiologi, Norwegian Institute of Public Health

Project participants

Eleni Zoumpoulia Papadopoulou, Avdeling for miljøeksponering og -epidemiologi, Norwegian Institute of Public Health

Start

03.01.2015

End

01.02.2022

Status

Active

Approvals

Regional committees for medical and health research ethics

Project owner/ Project manager

Norwegian Institute of Public Health

Project manager

Line Småstuen Haug

Participant at FHI

Eleni Zoumpoulia Papadopoulou